A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Authors
Keywords
-
Journal
Nature Chemical Biology
Volume 7, Issue 11, Pages 787-793
Publisher
Springer Nature America, Inc
Online
2011-09-26
DOI
10.1038/nchembio.695
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploiting synthetic lethal interactions for targeted cancer therapy
- (2011) H. Christian Reinhardt et al. CELL CYCLE
- Initial impact of the sequencing of the human genome
- (2011) Eric S. Lander NATURE
- Harnessing Our Opportunity to Make Primary Care Sustainable
- (2011) Jim McDermott NEW ENGLAND JOURNAL OF MEDICINE
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
- (2010) P. Workman et al. CANCER RESEARCH
- It's Diagnostics, Stupid
- (2010) René Bernards CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Synthetic lethality: General principles, utility and detection using genetic screens in human cells
- (2010) Sebastian M.B. Nijman FEBS LETTERS
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- c-Myc and eIF4F Constitute a Feedforward Loop That Regulates Cell Growth: Implications for Anticancer Therapy
- (2009) C.-J. Lin et al. CANCER RESEARCH
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- mTOR signaling at a glance
- (2009) M. Laplante et al. JOURNAL OF CELL SCIENCE
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Translating insights from the cancer genome into clinical practice
- (2008) Lynda Chin et al. NATURE
- The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes
- (2008) M. E. Hillenmeyer et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search